Want to join the conversation?
Richard Purkiss of Piper Jaffray asks for an estimate of Ibrance penetration broken down by line of therapy in the US. Pfizer Innovative Health President Albert Bourla said that $PFE has seen a first-line market share of 43%, and second and third-line market share of 46% and 24%, respectively.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?